Home/Filings/4/0001819790-21-000059
4//SEC Filing

Ackermann Michael 4

Accession 0001819790-21-000059

CIK 0001819790other

Filed

Dec 2, 7:00 PM ET

Accepted

Dec 3, 6:56 PM ET

Size

11.0 KB

Accession

0001819790-21-000059

Insider Transaction Report

Form 4
Period: 2021-12-01
Ackermann Michael
Director10% Owner
Transactions
  • Sale

    Common Stock

    2021-12-01$26.65/sh528$14,0711,204,016 total
  • Sale

    Common Stock

    2021-12-01$24.68/sh2,054$50,6931,205,353 total
  • Sale

    Common Stock

    2021-12-01$23.85/sh2,442$58,2421,207,407 total
  • Sale

    Common Stock

    2021-12-01$25.87/sh809$20,9291,204,544 total
Footnotes (5)
  • [F1]The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $23.24 to $24.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $24.28 to $25.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.51 to $26.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.53 to $27.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

Tarsus Pharmaceuticals, Inc.

CIK 0001819790

Entity typeother

Related Parties

1
  • filerCIK 0001791249

Filing Metadata

Form type
4
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 6:56 PM ET
Size
11.0 KB